Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CELZ
CELZ logo

CELZ Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Creative Medical Technology Holdings Inc (CELZ) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.470
1 Day change
6.01%
52 Week Range
6.250
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Creative Medical Technology Holdings Inc (CELZ) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks significant positive catalysts, has weak financial performance, and no strong trading signals. It is better to hold off on investing in this stock at this time.

Technical Analysis

The MACD is positive and expanding, indicating a potential bullish trend. However, the RSI is in the neutral zone at 72.853, and moving averages are converging, suggesting no clear trend. Key resistance levels are at 2.375 and 2.488, while support levels are at 2.008 and 1.895.

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • The stock has a high probability of declining (-1.45%) in the next week, and financial performance remains weak with negative EPS and net income.

Financial Performance

In Q4 2025, revenue remained flat YoY at 3000. Net income improved slightly by 1.81% YoY but remains negative at -1,887,674. EPS dropped significantly by -35.78% YoY to -0.7. Gross margin improved by 38.89% YoY but remains deeply negative at -964.77.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst ratings or price target changes available.

Wall Street analysts forecast CELZ stock price to rise
Analyst Rating
0
Wall Street analysts forecast CELZ stock price to rise
Buy
Hold
Sell
0
Current: 2.470
sliders
Low
0
Averages
0
High
0
0
Current: 2.470
sliders
Low
0
Averages
0
High
0
Roth Capital
Jonathan Aschoff
Buy
downgrade
$26 -> $20
AI Analysis
2025-06-04
Reason
Roth Capital
Jonathan Aschoff
Price Target
$26 -> $20
AI Analysis
2025-06-04
downgrade
Buy
Reason
Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Creative Medical to $20 from $26 and keeps a Buy rating on the shares. The company's clinical programs are on track, the analyst tells investors in a research note. The firm cites financial modeling adjustments for the target cut.

People Also Watch